Difference between revisions of "Acute myeloid leukemia, IDH-mutated"
Jump to navigation
Jump to search
m |
Tag: visualeditor |
||
| Line 1: | Line 1: | ||
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> | <!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> | ||
| − | <!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].--> | + | <!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->{| class="wikitable" style="text-align:center; width:50%;" |
| − | {| class="wikitable" style="text-align:center; width:50%;" | ||
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor''' | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor''' | ||
|- | |- | ||
| Line 34: | Line 33: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/ Stein et al. 2017] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/ Stein et al. 2017] | ||
| − | |style="background-color:#91cf61"|Phase I/II | + | | style="background-color:#91cf61" |Phase I/II |
| style="background-color:#8c96c6" |ORR: 40% | | style="background-color:#8c96c6" |ORR: 40% | ||
|- | |- | ||
| Line 46: | Line 45: | ||
===References=== | ===References=== | ||
# Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. [http://www.bloodjournal.org/content/130/6/722.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28588020 PubMed] | # Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. [http://www.bloodjournal.org/content/130/6/722.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28588020 PubMed] | ||
| + | =Investigational agents= | ||
| + | ''These are drugs under study with at least some promising results for this disease.'' | ||
| + | *[[Ivosidenib (AG-120)]] 500 mg PO once per day | ||
| + | |||
| + | === References === | ||
| + | # DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsd or Refractory AML. New England Journal of Medicine. Epub 2018 Jun 2. [https://www.nejm.org/doi/full/10.1056/NEJMoa1716984 link to original article] '''contains verified protocol''' | ||
[[Category:Acute myeloid leukemia regimens]] | [[Category:Acute myeloid leukemia regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Acute leukemias]] | [[Category:Acute leukemias]] | ||
Revision as of 01:32, 5 June 2018
| Page editor | |
|---|---|
 |
Martin Schoen, MD, MPH St. Louis, MO |
Note: these are biomarker-specific regimens for patients with IDH1 or IDH2-mutated AML, please see the main AML page for other regimens.
8 regimens on this page
8 variants on this page
|
Relapsed or refractory, salvage therapy
Enasidenib monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence | Efficacy |
|---|---|---|
| Stein et al. 2017 | Phase I/II | ORR: 40% |
This is the dose used in the phase II expansion cohort; enrolled patients were required to have IDH2-mutated advanced myeloid malignancies.
Chemotherapy
- Enasidenib (Idhifa) 100 mg PO once per day
28-day cycles
References
- Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. link to original article contains verified protocol link to PMC article PubMed
Investigational agents
These are drugs under study with at least some promising results for this disease.
- Ivosidenib (AG-120) 500 mg PO once per day
References
- DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsd or Refractory AML. New England Journal of Medicine. Epub 2018 Jun 2. link to original article contains verified protocol